iNexin™ Ophthalmic Solution
Preclinical
Phase 1
Phase 2
Phase 3
Ophthalmology
Persistent Corneal Epithelial Defects (PCED)
Orphan Drug Designation Pending
Recurrent Corneal Erosions (RCE)
iNexin™
Ophthalmic
Solution
Fuchs'
Dystrophy
Diabetic
Retinopathy
iNexin™ Ophthalmic Solution
Investigating indications with significant unmet medical needs
Corneal Disease
Corneal diseases can be caused by trauma, exposure, or underlying disease and consequences range from acute pain to infection and vision loss. iNexin Ophthalmic Solution is working in areas like PCED, RCE, and Fuchs’ to help alleviate corneal injuries.
Retinal Disease
Retinal diseases such as Diabetic Retinopathy impact the back of the eye and often result in retinal degeneration. They are the leading cause of vision loss or blindness. Despite progress in reducing disease prevalence, there remains a need for novel treatments that reduce patient burden and improve treatment outcomes.
iNexin™ Ophthalmic Solution has the potential to reduce patient burden and improve patient outcomes by regulating harmful inflammatory responses, stabilizing barrier function, and accelerating ocular healing.
In initial studies, iNexin™ demonstrated:
Acceleration of corneal re-epithelialization
Reduction of corneal edema and inflammation
Restoration of the ocular surface
Safe and tolerable delivery
Revolutionizing the Way the Body Responds to Injury
Xequel’s aCT1 technology platform is designed to stimulate healing by creating an improved injury response. Our proprietary aCT1 technology facilitates healing as it stabilizes gap and tight junctions to normalize cell-to-cell signaling, control the flow of fluid within tissues, and reduce harmful inflammation.
